Evidence map›Paper›PMID 38978599›Full record

ArticleResearch square2024

HDI-STARR-seq: Condition-specific enhancer discovery in mouse liver in vivo.

Ting-Ya Chang, David J Waxman

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ting-Ya ChangBoston University.
David J WaxmanBoston University.

Funding

Xenobiotic-responsive hepatic long non-coding RNAsR01ES024421 · NIEHS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WAXMAN, DAVID J · 2014 to 2024
$4.6M
Growth Hormone Regulation of Sex Differences in Liver MetabolismR01DK121998 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WAXMAN, DAVID J · 2019 to 2023
$2.5M
NIDDK NIH HHS R01 DK121998NIEHS NIH HHS R01 ES024421
6 · The paper itself

Abstract

Background: STARR-seq and other massively-parallel reporter assays are widely used to discover functional enhancers in transfected cell models, which can be confounded by plasmid vector-induced type-I interferon immune responses and lack the multicellular environment and endogenous chromatin state of complex mammalian tissues. Results: Here, we describe HDI-STARR-seq, which combines STARR-seq plasmid library delivery to the liver, by hydrodynamic tail vein injection (HDI), with reporter RNA transcriptional initiation driven by a minimal Conclusions: HDI-STARR-seq offers substantial improvements over current methodologies for large scale, functional profiling of enhancers, including condition-dependent enhancers, in liver tissue in vivo, and can be adapted to characterize enhancer activities in a variety of species and tissues by selecting suitable tissue- and species-specific promoter sequences.

Indexed as

chromatin accessibilityDNase-seqhydrodynamic tail vein injectionliver epigenetic marksliver sex differencesMPRASTARR-seqTCPOBOP

Identifiers

PMID38978599
PMCPMC11230509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.